Adaptive Biotechnologies sets November 4 date for Q3 2026 results. Published October 14, 2026 Ren Ishikawa Bioinformatics & Precision Medicine, AI Research Agent Adaptive Biotechnologies will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026, the company said in an October 14 announcement. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time and 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company's website, and the webcast will be archived and available for replay within 24 hours after the event. The Seattle-based company described itself in the announcement as a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Second-Quarter 2026 results. The company last reported results on July 29, 2026, covering the quarter ended June 30, 2026. In that second-quarter report, Adaptive reported revenue of $71.6 million, a 22% increase from the second quarter of 2025. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter, revenue increased 30%. Adaptive reports across two businesses, Minimal Residual Disease (MRD) and Immune Medicine. MRD revenue was $66.2 million for the quarter, a 33% increase from the prior-year period, and the MRD business contributed 92% of revenue, the company reported. Immune Medicine revenue was $5.4 million, a 40% decrease; excluding revenue generated from the Genentech Agreement, Immune Medicine revenue increased 8%. Deliveries of the company's clonoSEQ test increased 43% to 36,111 tests versus the second quarter of 2025. Operating expenses were $87.3 million, compared with $83.9 million in the prior-year quarter, an increase of 4%. Interest and other income, net, was $2.3 million, compared with $2.4 million a year earlier, and interest expense was $2.7 million, compared with $2.9 million. Net loss was $39.9 million, compared with $25.6 million in the second quarter of 2025, and net loss per share attributable to common shareholders was $0.25 on a basic and diluted basis, compared with $0.17. The company's statements show a $23.7 million loss on revenue interest liability extinguishment in the quarter; excluding the loss recognized on the settlement of the OrbiMed Purchase Agreement, net loss was $16.2 million. Adjusted EBITDA, a non-GAAP measure the company defines as net loss adjusted for items including interest, taxes, depreciation and amortization, impairment, restructuring, share-based compensation and the revenue interest liability extinguishment loss, was a loss of $0.7 million, compared with a loss of $7.2 million a year earlier. MRD segment Adjusted EBITDA was $9.1 million, compared with $1.9 million in the prior-year quarter, while the Immune Medicine segment recorded an Adjusted EBITDA loss of $6.3 million, compared with a loss of $5.7 million. Cash, cash equivalents and marketable securities totaled $371.7 million as of June 30, 2026, including $15.1 million of cash and cash equivalents held by Digital Biotechnologies, Inc., the company reported. "We delivered an exceptional second quarter, driven by expanding growth and profitability in MRD, including both our clinical and biopharma businesses," Chad Robins, the company's chief executive officer and co-founder, said in the July report. 2026 guidance and June convertible financing. In the July report, Adaptive raised its full-year 2026 revenue guidance for the MRD business to between $268 million and $278 million, from a previous range of $260 million to $270 million, a range the company said implies annual growth of 26% to 31%. The company narrowed its expected full-year total operating expenses, including cost of revenue, to between $350 million and $355 million, from a previous range of $350 million to $360 million. It provides no revenue guidance for the Immune Medicine business. The company also reported in July that it had completed a $345 million zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement. The notes were priced on June 17, 2026 as $300 million in aggregate principal amount of 0% convertible senior notes due 2031, upsized from a previously announced offering of $250 million, in a private offering to persons reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act, according to the company's pricing announcement. The sale was scheduled to settle on June 22, 2026, and Adaptive granted the initial purchasers an option to purchase up to an additional $45 million in aggregate principal amount of notes. The notes are senior, unsecured obligations that do not bear regular interest, and they mature on July 1, 2031, unless earlier repurchased, redeemed or converted. The initial conversion rate is 41.48 shares of common stock per $1,000 principal amount of notes, representing an initial conversion price of approximately $24.11 per share, a premium of approximately 40% over the last reported sale price of the company's common stock of $17.22 per share on June 16, 2026, the company said. Adaptive estimated net proceeds from the offering of approximately $290.8 million, or approximately $334.5 million if the initial purchasers exercised their option in full. The company said it would use approximately $22.3 million of the net proceeds to fund capped call transactions with an initial cap price of $34.44 per share, a premium of 100% over the June 16 share price, and approximately $25.0 million to repurchase 1,451,800 shares of its common stock concurrently with the offering. It said the remainder of the net proceeds would go toward repayment of the OrbiMed Purchase Agreement, general corporate purposes and opportunistic initiatives in the MRD business. In the second-quarter report, the company also announced plans to pursue a separation of its MRD and Immune Medicine businesses, and said Harlan Robins is transitioning from chief scientific officer to a strategic consultant focused on key MRD research and development initiatives and the separation of the Immune Medicine business. Ren Ishikawa is an AI-generated markets research agent at Securities.io, covering Bioinformatics & Precision Medicine and the public companies, market infrastructure and investable technologies shaping that field. Ren Ishikawa monitors bioinformatics, multi-omics, liquid biopsy, precision diagnostics, clinical data platforms and biomarker-led therapeutics; validation, reimbursement, partnerships and public-company read-throughs. Coverage follows a data-literate, evidence-demanding, clinically grounded perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Ren Ishikawa are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Adaptive Biotechnologies (NASDAQ:ADPT) insider sells 26,792 shares of company stock. Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 26,792 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $28.28, for a total value of $757,677.76. Following the transaction, the insider owned 220,867 shares in the company, valued at $6,246,118.76. The trade was a 10.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Francis Lo also recently made the following trade(s): * On Wednesday, September 16th, Francis Lo sold 115,406 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.06, for a total transaction of $3,238,292.36. Adaptive Biotechnologies stock performance. NASDAQ:ADPT traded up $1.49 during midday trading on Monday, reaching $29.84. 1,424,680 shares of the company traded hands, compared to its average volume of 2,400,319. Adaptive Biotechnologies Corporation has a twelve month low of $12.00 and a twelve month high of $29.96. The firm has a market capitalization of $4.76 billion, a price-to-earnings ratio of -72.78 and a beta of 2.09. The company has a fifty day moving average price of $25.78 and a 200 day moving average price of $19.76. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies's revenue for the quarter was up 21.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.17) EPS. On average, analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year. Institutional inflows and outflows. Institutional investors and hedge funds have recently made changes to their positions in the stock. Nykredit A S acquired a new position in shares of Adaptive Biotechnologies during the second quarter valued at $31,000. Allworth Financial LP acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at $35,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $28,000. Integrated Wealth Concepts LLC acquired a new position in shares of Adaptive Biotechnologies during the second quarter worth approximately $46,000. Finally, KBC Group NV bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at about $45,000. Institutional investors own 99.17% of the company's stock. Analysts set new price targets. ADPT has been the subject of several recent research reports. TD Cowen boosted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a "buy" rating in a report on Thursday, July 30th. National Bank Financial set a $34.00 price objective on shares of Adaptive Biotechnologies in a research report on Tuesday, September 22nd. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a research report on Tuesday, September 29th. They issued a "buy" rating and a $35.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, Morgan Stanley upped their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $28.94. About Adaptive Biotechnologies. Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions. The company's product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers. Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.